| Venture Medical 21 Inc | |
|
91-896 Makule Rd Ste 102 Ewa Beach HI 96706-2543 | |
| (808) 689-4414 | |
| (808) 689-7115 |
| Full Name | Venture Medical 21 Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 91-896 Makule Rd Ste 102, Ewa Beach, Hawaii |
| Authorized Official Name and Position | Jose D Reque (PRESIDENT) |
| Authorized Official Contact | 8085317878 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Venture Medical 21 Inc 810 Richards St Ste 990 Honolulu HI 96813-4722 Ph: (808) 531-7878 | Venture Medical 21 Inc 91-896 Makule Rd Ste 102 Ewa Beach HI 96706-2543 Ph: (808) 689-4414 |
| NPI Number | 1851647952 |
|---|---|
| Provider Enumeration Date | 07/26/2012 |
| Last Update Date | 08/15/2014 |
| Medicare PECOS PAC ID | 7810147832 |
|---|---|
| Medicare Enrollment ID | O20121026000580 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.
Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851647952 | NPI | - | NPPES |
| W8141213401 | Other | HI | STATE OF HAWAII |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Jose C De Leon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1275639866 PECOS PAC ID: 3870519036 Enrollment ID: I20051018000569 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.
Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.
› Verified 4 days ago
| Provider Name | Macrina U Vicerra-jaena |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992758015 PECOS PAC ID: 0547410490 Enrollment ID: I20121030000447 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.
Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.
› Verified 4 days ago
| Provider Name | Jacqueline Y Chacon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023376779 PECOS PAC ID: 5799936076 Enrollment ID: I20121114000299 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.
Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.
› Verified 4 days ago
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.
Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.
› Verified 4 days ago
James M Warner Md Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 91-2141 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-678-7370 Fax: 808-678-7240 | |
Drt Medical Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 91-2141 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-678-7000 | |
Empower Health Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 91-6390 Kapolei Pkwy, Ewa Beach, HI 96706 Phone: 808-691-4600 | |
Access Medical Clinics Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 91-1401 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-285-2448 | |
West Oahu Acupuncture And Integrative Medicine Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 91-1123 Keaunui Dr Ste 223, Ewa Beach, HI 96706 Phone: 808-638-4559 Fax: 781-998-2412 | |
Waianae District Comprehensive Health And Hospital Board, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 91-1841 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-697-3300 | |
Rachel Tortolini Md,llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 91-896 Makule Rd Ste 102, Ewa Beach, HI 96706 Phone: 808-689-4414 Fax: 808-689-7115 |